(ACRV) Acrivon Therapeutics - Ratings and Ratios
Cancer, Drugs, Diagnostics, Platform, Pipeline
ACRV EPS (Earnings per Share)
ACRV Revenue
Description: ACRV Acrivon Therapeutics
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary generative phosphoproteomics platform to develop targeted oncology treatments. By utilizing its Acrivon Predictive Precision Proteomics (AP3) platform, the company creates companion diagnostics, known as OncoSignature, to identify patients likely to benefit from its therapies. This precision medicine approach enables Acrivon to tailor its treatments to specific patient populations, potentially increasing their efficacy.
The companys pipeline includes ACR-368, a CHK1 and CHK2 inhibitor being evaluated for the treatment of endometrial, platinum-resistant ovarian cancer, and certain squamous cell carcinomas. Additionally, Acrivon is developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor, and a preclinical cell cycle program. With a focus on precision oncology, Acrivon aims to address the needs of patients with tumors predicted to be sensitive to its medicines.
From a technical analysis perspective, ACRVs stock price has been trending downward, with its short-term and long-term moving averages (SMA20, SMA50, and SMA200) indicating a bearish sentiment. The Average True Range (ATR) suggests significant volatility, with a 16.48% daily price swing. Given the current price of $1.25, the stock is near its 52-week low of $1.10. However, a potential buying opportunity may arise if the stock price stabilizes above its SMA20 at $1.36.
Fundamentally, Acrivon Therapeutics has a relatively small market capitalization of $37.63M USD, and its lack of profitability is reflected in its negative P/E ratio and Return on Equity (RoE) of -46.18. As a clinical-stage biopharmaceutical company, significant investments in research and development are expected. The success of its lead candidates, particularly ACR-368, will be crucial in determining the companys future prospects.
Forecasting the future performance of ACRV requires a combination of technical and fundamental analysis. Based on the current technical trends and fundamental data, a potential price target for ACRV could be around $2.50, representing a 100% increase from its current price. This would be contingent upon the company announcing positive clinical trial results for ACR-368, securing additional funding, or achieving significant milestones in its pipeline development. However, the high volatility and bearish sentiment in the stocks technical indicators suggest that there are substantial risks associated with this investment.
Additional Sources for ACRV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ACRV Stock Overview
Market Cap in USD | 41m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2022-11-15 |
ACRV Stock Ratings
Growth Rating | -64.5 |
Fundamental | -58.0 |
Dividend Rating | 0.0 |
Rel. Strength | -80.4 |
Analysts | 4.33 of 5 |
Fair Price Momentum | 0.91 USD |
Fair Price DCF | - |
ACRV Dividends
Currently no dividends paidACRV Growth Ratios
Growth Correlation 3m | -56% |
Growth Correlation 12m | -90.9% |
Growth Correlation 5y | -74.3% |
CAGR 5y | -62.24% |
CAGR/Max DD 5y | -0.65 |
Sharpe Ratio 12m | -0.35 |
Alpha | -108.03 |
Beta | 2.341 |
Volatility | 90.29% |
Current Volume | 125.8k |
Average Volume 20d | 333.3k |
As of July 06, 2025, the stock is trading at USD 1.29 with a total of 125,785 shares traded.
Over the past week, the price has changed by +7.50%, over one month by +4.88%, over three months by -14.57% and over the past year by -81.75%.
No, based on ValueRay´s Fundamental Analyses, Acrivon Therapeutics (NASDAQ:ACRV) is currently (July 2025) a stock to sell. It has a ValueRay Fundamental Rating of -58.00 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACRV is around 0.91 USD . This means that ACRV is currently overvalued and has a potential downside of -29.46%.
Acrivon Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ACRV.
- Strong Buy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, ACRV Acrivon Therapeutics will be worth about 1.1 in July 2026. The stock is currently trading at 1.29. This means that the stock has a potential downside of -15.5%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 11.3 | 778.3% |
Analysts Target Price | 11.3 | 778.3% |
ValueRay Target Price | 1.1 | -15.5% |